Cargando…
Nitrofurantoin: what is the evidence for current UK guidance?
Three days of nitrofurantoin at 100 mg twice daily is recommended as first-line treatment for uncomplicated urinary tract infection (UTI) in evidence-based guidelines across the UK. A review of international guidelines shows that the evidence base has been interpreted in very different ways. UK guid...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631823/ https://www.ncbi.nlm.nih.gov/pubmed/37738416 http://dx.doi.org/10.1093/jac/dkad287 |
_version_ | 1785146098724110336 |
---|---|
author | Kashouris, Eleanor Joseph, Amelia Lewis, Tom |
author_facet | Kashouris, Eleanor Joseph, Amelia Lewis, Tom |
author_sort | Kashouris, Eleanor |
collection | PubMed |
description | Three days of nitrofurantoin at 100 mg twice daily is recommended as first-line treatment for uncomplicated urinary tract infection (UTI) in evidence-based guidelines across the UK. A review of international guidelines shows that the evidence base has been interpreted in very different ways. UK guidelines are unusual in promoting short (3 day) courses, and we find little direct evidence to support this. Although ‘short’ courses of antibiotics for other agents may provide optimum balance between providing effective treatment whilst reducing selective pressure driving resistance amongst colonizing microbial flora, it remains unclear that course lengths can be extrapolated to nitrofurantoin. Three days of nitrofurantoin may indeed be a useful intervention in a large group of patients. However, without supporting evidence and because clinical response should be expected to vary widely, it is unclear that establishing and promoting an antibiotic duration for UTI is the best approach to optimizing prescribing in this important area. |
format | Online Article Text |
id | pubmed-10631823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106318232023-11-15 Nitrofurantoin: what is the evidence for current UK guidance? Kashouris, Eleanor Joseph, Amelia Lewis, Tom J Antimicrob Chemother Review Three days of nitrofurantoin at 100 mg twice daily is recommended as first-line treatment for uncomplicated urinary tract infection (UTI) in evidence-based guidelines across the UK. A review of international guidelines shows that the evidence base has been interpreted in very different ways. UK guidelines are unusual in promoting short (3 day) courses, and we find little direct evidence to support this. Although ‘short’ courses of antibiotics for other agents may provide optimum balance between providing effective treatment whilst reducing selective pressure driving resistance amongst colonizing microbial flora, it remains unclear that course lengths can be extrapolated to nitrofurantoin. Three days of nitrofurantoin may indeed be a useful intervention in a large group of patients. However, without supporting evidence and because clinical response should be expected to vary widely, it is unclear that establishing and promoting an antibiotic duration for UTI is the best approach to optimizing prescribing in this important area. Oxford University Press 2023-09-20 /pmc/articles/PMC10631823/ /pubmed/37738416 http://dx.doi.org/10.1093/jac/dkad287 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kashouris, Eleanor Joseph, Amelia Lewis, Tom Nitrofurantoin: what is the evidence for current UK guidance? |
title | Nitrofurantoin: what is the evidence for current UK guidance? |
title_full | Nitrofurantoin: what is the evidence for current UK guidance? |
title_fullStr | Nitrofurantoin: what is the evidence for current UK guidance? |
title_full_unstemmed | Nitrofurantoin: what is the evidence for current UK guidance? |
title_short | Nitrofurantoin: what is the evidence for current UK guidance? |
title_sort | nitrofurantoin: what is the evidence for current uk guidance? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631823/ https://www.ncbi.nlm.nih.gov/pubmed/37738416 http://dx.doi.org/10.1093/jac/dkad287 |
work_keys_str_mv | AT kashouriseleanor nitrofurantoinwhatistheevidenceforcurrentukguidance AT josephamelia nitrofurantoinwhatistheevidenceforcurrentukguidance AT lewistom nitrofurantoinwhatistheevidenceforcurrentukguidance |